Once-weekly exenatide vs once- or twice-daily insulin detemir: randomised, open-label clinical trial of efficacy and safety in patients with Type 2 diabetes inadequately controlled with metformin alone or with sulphonylureas

被引：0
|
作者：
Davies, M. [1 ]
Heller, S. [2 ]
Sreenan, S. [3 ]
Sapin, H. [4 ]
Adetunji, O. [5 ]
Tahbaz, A. [5 ]
Vora, J. [6 ]
机构：
[1] Univ Leicester, Leicester, Leics, England
[2] Univ Sheffield, Acad Unit Diabet Endocrinol & Metab, Sheffield, S Yorkshire, England
[3] Connolly Hosp, Royal Coll Surg Ireland, Dublin, Ireland
[4] Lilly France, Suresnes, France
[5] Eli Lilly & Co, Basingstoke, Hants, England
[6] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England
来源：
DIABETIC MEDICINE | 2013年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：57 / 58
页数：2
相关论文
共 50 条
  • [1] Once-Weekly Exenatide Versus Once- or Twice-Daily Insulin Detemir Randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas
    Davies, Melanie
    Heller, Simon
    Sreenan, Seamus
    Sapin, Helene
    Adetunji, Omolara
    Tahbaz, Arash
    Vora, Jiten
    DIABETES CARE, 2013, 36 (05) : 1368 - 1376
  • [2] Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus
    Ji, Linong
    Onishi, Yukiko
    Ahn, Chul Woo
    Agarwal, Pankaj
    Chou, Chien-Wen
    Haber, Harry
    Guerrettaz, Kelly
    Boardman, Marilyn K.
    JOURNAL OF DIABETES INVESTIGATION, 2013, 4 (01) : 53 - 61
  • [3] Efficacy and safety of once-weekly exenatide after switching from twice-daily exenatide in patients with type 2 diabetes
    Watanabe, Yuusuke
    Saisho, Yoshifumi
    Inaishi, Jun
    Kou, Kinsei
    Yamauchi, Akira
    Kanazawa, Yasuhiko
    Okubo, Yoshiaki
    Tokui, Mikiya
    Imai, Takatoshi
    Murakami, Rie
    Tsuchiya, Tami
    Sasaki, Hironobu
    Masaoka, Tatsuhiro
    Irie, Junichiro
    Meguro, Shu
    Itoh, Hiroshi
    JOURNAL OF DIABETES INVESTIGATION, 2020, 11 (02) : 382 - 388
  • [4] Efficacy and safety of once-weekly exenatide after switching from twice-daily exenatide in patients with type 2 diabetes
    Saisho, Y.
    Watanabe, Y.
    Inaishi, J.
    Kou, K.
    Yamauchi, A.
    Kanazawa, Y.
    Okubo, Y.
    Tokui, M.
    Imai, T.
    Masaoka, T.
    Irie, J.
    Meguro, S.
    Itoh, H.
    DIABETOLOGIA, 2019, 62 : S374 - S374
  • [5] Clinical Implications of Exenatide as a Twice-Daily or Once-Weekly Therapy for Type 2 Diabetes
    Aroda, Vanita R.
    DeYoung, Mary Beth
    POSTGRADUATE MEDICINE, 2011, 123 (05) : 228 - 238
  • [6] Impact of Renal Function on Efficacy and Safety of Autoinjected Exenatide Once-Weekly Suspension vs. Exenatide Twice-Daily in Type 2 Diabetes
    Wysham, Carol H.
    Hardy, Elise
    Wang, Hui
    Rosenstock, Julio
    DIABETES, 2017, 66 : A300 - A300
  • [7] Comparison of once-weekly with twice-daily exenatide in the treatment of type 2 diabetes (DURATION-1 trial)
    Raskin, Philip
    Mohan, Alok
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (13) : 2269 - 2271
  • [8] Patient-reported outcomes in a trial of exenatide once weekly vs insulin detemir in patients with Type 2 diabetes treated with metformin alone or with sulphonylurea
    Heller, S.
    Adetunji, O.
    Tahbaz, A.
    Wintle, M.
    Davies, M.
    DIABETIC MEDICINE, 2013, 30 : 58 - 58
  • [9] Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
    Drucker, Daniel J.
    Buse, John B.
    Taylor, Kristin
    Kendall, David M.
    Trautmann, Michael
    Zhuang, Dangliang
    Porter, Lisa
    LANCET, 2008, 372 (9645): : 1240 - 1250
  • [10] Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
    Buse, John B.
    Nauck, Michael
    Forst, Thomas
    Sheu, Wayne H-H
    Shenouda, Sylvia K.
    Heilmann, Cory R.
    Hoogwerf, Byron J.
    Gao, Aijun
    Boardman, Marilyn K.
    Fineman, Mark
    Porter, Lisa
    Schernthaner, Guntram
    LANCET, 2013, 381 (9861): : 117 - 124
12345